| dc.creator | Speletas, M. | en |
| dc.creator | Vyzantiadis, T. A. | en |
| dc.creator | Kalala, F. | en |
| dc.creator | Plastiras, D. | en |
| dc.creator | Kokoviadou, K. | en |
| dc.creator | Antoniadis, A. | en |
| dc.creator | Korantzis, I. | en |
| dc.date.accessioned | 2015-11-23T10:48:15Z | |
| dc.date.available | 2015-11-23T10:48:15Z | |
| dc.date.issued | 2008 | |
| dc.identifier | 10.1080/13693780701558969 | |
| dc.identifier.issn | 1369-3786 | |
| dc.identifier.uri | http://hdl.handle.net/11615/33282 | |
| dc.description.abstract | In this report we describe a patient suffering from chronic myeloid leukemia (CML), who was treated for 4.5 years with imatinib and developed pneumonia caused by two Candida species, i.e., C. krusei and C. glabrata. The patient was in complete hematologic remission and molecular analyses did not display the presence of TLR2-R752Q, TLR4-D299G and TLR4-T399I polymorphisms that may predispose individuals to fungal infections. This case report indicates that in some patients, as previously observed, the long-term administration of targeted therapy might affect immunity and predispose patients to opportunistic and life-threatening fungal infections. | en |
| dc.source.uri | <Go to ISI>://WOS:000254869200008 | |
| dc.subject | chronic myeloid leukemia (CML) | en |
| dc.subject | Candida krusei | en |
| dc.subject | Candida glabrata | en |
| dc.subject | imatinib | en |
| dc.subject | TLR | en |
| dc.subject | CHRONIC MYELOGENOUS LEUKEMIA | en |
| dc.subject | TOLL-LIKE RECEPTORS | en |
| dc.subject | IN-VITRO | en |
| dc.subject | PROLIFERATION | en |
| dc.subject | INFECTION | en |
| dc.subject | DISEASE | en |
| dc.subject | Infectious Diseases | en |
| dc.subject | Mycology | en |
| dc.subject | Veterinary Sciences | en |
| dc.title | Pneumonia caused by Candida krusei and Candida glabrata in a patient with chronic myeloid leukemia receiving imatinib mesylate treatment | en |
| dc.type | journalArticle | en |
